209 related articles for article (PubMed ID: 3044273)
1. [Comparison of methods for evaluating the nephrotoxicity of cisplatin].
Suzumori K; Yasui Y; Suzumori K; Yagami Y; Seki T
Gan To Kagaku Ryoho; 1988 Aug; 15(8):2251-6. PubMed ID: 3044273
[TBL] [Abstract][Full Text] [Related]
2. [Studies on serum and urinary alpha 1-microglobulin levels as parameter of the renal function--renal function observed after CDDP administration].
Ujiie T; Maruta H; Ito N
Hinyokika Kiyo; 1988 May; 34(5):790-6. PubMed ID: 2459938
[TBL] [Abstract][Full Text] [Related]
3. [Measurement of creatinine clearance and urinary NAG for the evaluation of cis-platinum induced nephrotoxicity].
Kubota A; Yoshida T; Tsukuda M; Furukawa S; Miyata K; Mochimatsu I; Sawaki S
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2599-605. PubMed ID: 2774590
[TBL] [Abstract][Full Text] [Related]
4. Urinary excretion of beta 2-microglobulin and N-acetyl-beta-D-glucosaminidase in advanced neuroblastoma patients receiving cis-diamminedichloroplatinum(II).
Ikeda H; Nagashima K; Okumura H; Takahashi A; Matsuyama S; Nagamachi Y
Eur J Surg Oncol; 1988 Feb; 14(1):17-20. PubMed ID: 3278937
[TBL] [Abstract][Full Text] [Related]
5. [Determination of urinary N-acetyl-beta-D-glucosaminidase (NAG) excretion as a parameter of nephrotoxicity due to cis-platin and the effect of fosfomycin (FOM) on its nephrotoxicity].
Matsuoka R; Inoue T; Miyamura K; Mizutani K; Koike S; Mori H; Kigawa T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Nov; 38(11):2037-44. PubMed ID: 3794453
[TBL] [Abstract][Full Text] [Related]
6. Comparison of methods of evaluating nephrotoxicity of cis-platinum.
Jones BR; Bhalla RB; Mladek J; Kaleya RN; Gralla RJ; Alcock NW; Schwartz MK; Young CW; Reidenberg MM
Clin Pharmacol Ther; 1980 Apr; 27(4):557-62. PubMed ID: 6987030
[TBL] [Abstract][Full Text] [Related]
7. [Clinical investigation of cis-platinum nephrotoxicity in 244 cases of primary lung cancer].
Soejima A; Inoue T; Suzuki M; Waku M; Nakabayashi K; Kitamoto K; Nagasawa T
Nihon Jinzo Gakkai Shi; 1992 Jul; 34(7):801-6. PubMed ID: 1479719
[TBL] [Abstract][Full Text] [Related]
8. Mercury in dental restoration: is there a risk of nephrotoxicity?
Mortada WL; Sobh MA; El-Defrawy MM; Farahat SE
J Nephrol; 2002; 15(2):171-6. PubMed ID: 12018634
[TBL] [Abstract][Full Text] [Related]
9. [Effects of urinastatin against nephrotoxicity of cisplatinum].
Arakawa A; Kato N; Asai H; Yasui Y; Suzumori K; Suzumori K; Yagami Y
Gan To Kagaku Ryoho; 1990 Nov; 17(11):2229-34. PubMed ID: 2241187
[TBL] [Abstract][Full Text] [Related]
10. [A clinical evaluation of the protective effect of fosfomycin (FOM) against the cis-diamminedichloroplatinum (CDDP)-induced nephrotoxicity].
Saito M; Masaki T; Kato H; Numasaka K
Hinyokika Kiyo; 1988 May; 34(5):782-9. PubMed ID: 3051938
[TBL] [Abstract][Full Text] [Related]
11. [Cisplatin and ovarian carcinoma--early detection of cisplatin-induced nephrotoxicity].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Jun; 37(6):888-96. PubMed ID: 4040542
[TBL] [Abstract][Full Text] [Related]
12. [Acute nephrotoxicity by CDDP (on tubular damage)].
Higuchi K; Negoro Y; Suzuki M; Noguchi M; Nakanishi M; Ishihara M; Nakano M
Gan To Kagaku Ryoho; 1991 Jan; 18(1):85-9. PubMed ID: 1987905
[TBL] [Abstract][Full Text] [Related]
13. [Effects of combination chemotherapy with cis-diamminedichloroplatinum (II) (CDDP) on renal function in patients with urogenital malignancies].
Kawamura J; Hida S; Higashi Y; Yamauchi T; Soeda A; Yoshida O
Hinyokika Kiyo; 1985 Feb; 31(2):207-21. PubMed ID: 4040315
[TBL] [Abstract][Full Text] [Related]
14. [Effects of fractionated low dose Cisplatin on renal functions of patients with gastric carcinoma].
Li Y; Shen L; Li J; Jin ML
Ai Zheng; 2007 Dec; 26(12):1354-6. PubMed ID: 18076800
[TBL] [Abstract][Full Text] [Related]
15. Prognostic values of serum cystatin C and beta2 microglobulin, urinary beta2 microglobulin and N-acetyl-beta-D-glucosaminidase in early acute renal failure after liver transplantation.
Hei ZQ; Li XY; Shen N; Pang HY; Zhou SL; Guan JQ
Chin Med J (Engl); 2008 Jul; 121(14):1251-6. PubMed ID: 18713542
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
[TBL] [Abstract][Full Text] [Related]
17. [Relation of enzyme distribution in the kidney and increase pattern of urinary N-acetyl-beta-D-glucosaminidase (NAG) and gamma-glutamyl transpeptidase (gamma-GTP) activities following CDDP administration].
Takahashi T; Yoshida K; Nakame Y; Saitoh H
Hinyokika Kiyo; 1987 Oct; 33(10):1569-74. PubMed ID: 2895573
[TBL] [Abstract][Full Text] [Related]
18. [Influences of percutaneous nephrolithotomy on renal function, an observation using the NAG-index and beta 2-microglobulin as indices].
Yajima I; Nishimura T; Yoshida K; Tomita M; Hikima N; Kawamura N; Tsuboi N; Honda R; Akimoto M
Hinyokika Kiyo; 1987 May; 33(5):662-8. PubMed ID: 3310555
[TBL] [Abstract][Full Text] [Related]
19. [Preventive effect of prostaglandin E1 on cisplatin-induced nephrotoxicity].
Takayama K; Nakanishi Y; Takano K; Harada T; Inoue K; Osaki S; Minami T; Hara N
Gan To Kagaku Ryoho; 1999 Mar; 26(4):503-8. PubMed ID: 10097747
[TBL] [Abstract][Full Text] [Related]
20. [NAG (N-acetyl-beta-D-glucosaminidase)--a sensitive marker for disorders of kidney function].
Skrezek C; Bertermann H; Schulz FP; König B
Urologe A; 1990 Jan; 29(1):27-31. PubMed ID: 2316078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
